You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 11, March 21, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Men's Health
 •Men's Health, Other
 •Urinary Tract Disorders
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their randomized controlled trial, Dr Kaplan and colleagues1 found that use of tolterodine (an antimuscarinic) and tamsulosin (an {alpha} blocker) significantly improved outcomes in men with lower urinary tract symptoms and overactive bladder. Lower urinary tract symptoms in older men have often been attributed to benign prostatic hyperplasia (BPH). Because most of the men in this trial were older than 60 years and because their prostate volumes were not measured, a question that remains unanswered is whether a 5{alpha}-reductase inhibitor could have similarly decreased symptoms of urgency or urge incontinence. It would be informative to have a trial comparing antimuscarinics to a 5{alpha}-reductase inhibitor; it is quite possible that overactive bladder plays more of role than BPH in men with complaints of urinary urgency or urge incontinence.

Financial Disclosures: Dr Chai reports receiving research support from Pfizer and serving on the advisory board for Astellas.

Toby C. Chai, MD
tchai@smail.umaryland.edu
Division of Urology
University of Maryland School of Medicine
Baltimore

1. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006;296:2319-2328. FREE FULL TEXT

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2007;297:1191-1192.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
William Andrew Bell and Naseem Amarshi
JAMA. 2007;297(11):1192.
EXTRACT | FULL TEXT  

Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder
James G. Young and Kesavapilla Subramonian
JAMA. 2007;297(11):1192-1193.
EXTRACT | FULL TEXT  

Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder—Reply
Steven A. Kaplan, Claus G. Roehrborn, Eric S. Rovner, Tamara Bavendam, and Zhonghong Guan
JAMA. 2007;297(11):1193.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Multiple Serotonergic Brainstem Abnormalities in Sudden Infant Death Syndrome
David S. Paterson, Felicia L. Trachtenberg, Eric G. Thompson, Richard A. Belliveau, Alan H. Beggs, Ryan Darnall, Amy E. Chadwick, Henry F. Krous, and Hannah C. Kinney
JAMA. 2006;296(17):2124-2132.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.